Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities

References

• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Mitchell A, van Rhee F, et al. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124(20):3043–3051.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543–556.
   PubMed Web of Science ®Google Scholar
• Nishimura KK, Barlogie B, van Rhee F, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020;4(2):422–431.
   PubMed Web of Science ®Google Scholar
• Lonial S, Boise LH, Kaufman J. How I treat high-risk myeloma. Blood. 2015;126(13):1536–1543.
   PubMed Web of Science ®Google Scholar
• Maura F, Bolli N, Angelopoulos N, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019;10(1):3835.
   PubMedGoogle Scholar
• Shah V, Sherborne AL, Johnson DC, et al. Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia. 2020;34(11):3091–3096.
   PubMed Web of Science ®Google Scholar
• Giri S, Huntington SF, Wang R, et al. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Adv. 2020;4(10):2245–2253.
   PubMed Web of Science ®Google Scholar
• Fabris S, Ronchetti D, Agnelli L, et al. Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia. 2007;21(5):1113–1116.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Gertz MA. 1q+: amplifying the bad genes in myeloma. Leuk Lymphoma. 2017;58(8):1771–1773.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Shi CX, Bruins LA, et al. Loss of FAM46C promotes cell survival in myeloma. Cancer Res. 2017;77(16):4317–4327.
   PubMed Web of Science ®Google Scholar
• Bisht K, Walker B, Kumar SK, et al. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Expert Rev Hematol. 2021;14(12):1099–1114.
   PubMed Web of Science ®Google Scholar
• D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a european myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406–3418.
   PubMed Web of Science ®Google Scholar
• Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021;11(4):83.
   PubMed Web of Science ®Google Scholar
• Stella F, Pedrazzini E, Baialardo E, et al. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders. Blood Cells Mol Dis. 2014;53(3):110–117.
   PubMed Web of Science ®Google Scholar
• Luo S, Su T, Zhou X, et al. Chromosome 1 instability in multiple myeloma: aberrant gene expression, pathogenesis, and potential therapeutic target. Faseb J. 2022;36:e22341.
   PubMed Web of Science ®Google Scholar
• Hanamura I. Gain/amplification of chromosome arm 1q21 in multiple myeloma. Cancers. 2021;13(2):256.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD, Jr., Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276–2284.
   PubMed Web of Science ®Google Scholar
• Li F, Xu Y, An G[, et al. The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment. Zhonghua Xue Ye Xue Za Zhi. 2013;34:862–867.
   PubMedGoogle Scholar
• Liu XL, Yang PY, Yu XY[, et al. Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients. Zhonghua Xue Ye Xue Za Zhi. 2018;39:408–413.
   PubMedGoogle Scholar
• Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. Cells. 2021;10(2):336.
   PubMed Web of Science ®Google Scholar
• Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9(4):313–325.
   PubMed Web of Science ®Google Scholar
• Xing DH, Wang JH, Zhao ZG. The role of 1q21 gain on the prognosis of multiple myeloma. J Nutr Oncol. 2021;6(2):50–56.
   Google Scholar
• Burroughs Garcia J, Eufemiese RA, Storti P, et al. Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets. Cells. 2021;10(6):1360.
   PubMed Web of Science ®Google Scholar
• Al-Odat O, von Suskil M, Chitren R, et al. Mcl-1 inhibition: managing malignancy in multiple myeloma. Front Pharmacol. 2021;12:699629.
   PubMedGoogle Scholar
• Ting DU, Song Y, Ray A, et al. Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in myeloma. Blood. 2021;138(Supplement 1):1591–1591.
   Google Scholar
• Audil HY, Cook JM, Greipp PT, et al. Prognostic significance of acquired 1q22 gain in multiple myeloma. Am J Hematol. 2022;97(1):52–59.
   PubMed Web of Science ®Google Scholar
• Tagde A, Rajabi H, Bouillez A, et al. MUC1-C drives MYC in multiple myeloma. Blood. 2016;127(21):2587–2597.
   PubMed Web of Science ®Google Scholar
• Sherbenou DW, Aftab BT, Su Y, et al. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016;126(12):4640–4653.
   PubMed Web of Science ®Google Scholar
• Li F, Hu L, Xu Y, et al. Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma. Leukemia. 2016;30(5):1197–1201.
   PubMed Web of Science ®Google Scholar
• Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56-65–e65.
   PubMed Web of Science ®Google Scholar
• Kanasugi J, Hanamura I, Ota A, et al. Biallelic loss of FAM46C triggers tumor growth with concomitant activation of akt signaling in multiple myeloma cells. Cancer Sci. 2020;111(5):1663–1675.
   PubMed Web of Science ®Google Scholar
• Mroczek S, Chlebowska J, Kuliński TM, et al. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. Nat Commun. 2017;8(1):619.
   PubMedGoogle Scholar
• Boyd KD, Ross FM, Walker BA, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17(24):7776–7784.
   PubMed Web of Science ®Google Scholar
• McAvera R. Investigating the role of TRIM33 in the DNA damage response in multiple myeloma. Diss. Queen’s University Belfast. 2022;
   Google Scholar
• Hebraud B, Leleu X, Lauwers-Cances V, et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2014;28(3):675–679.
   PubMed Web of Science ®Google Scholar
• Sun F, Cheng Y, Riordan JD, et al. WDR26 and MTF2 are therapeutic targets in multiple myeloma. J Hematol Oncol. 2021;14(1):203.
   PubMed Web of Science ®Google Scholar
• Robak P, Jarych D, Mikulski D, et al. The prognostic value of whole-blood PSMB5, CXCR4, POMP, and RPL5 mRNA expression in patients with multiple myeloma treated with bortezomib. Cancers (Basel). 2021;13(5):951.
   PubMed Web of Science ®Google Scholar
• Hofman IJF, van Duin M, De Bruyne E, et al. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia. 2017;31(8):1706–1714.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Jiang A, et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 2010;45(1):117–121.
   PubMed Web of Science ®Google Scholar
• Abdollahi P, Kohn M, Borset M. Protein tyrosine phosphatases in multiple myeloma. Cancer Lett. 2021;501:105–113.
   PubMed Web of Science ®Google Scholar
• Leone PE, Walker BA, Jenner MW, et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res. 2008;14(19):6033–6041.
   PubMed Web of Science ®Google Scholar
• Biran N, Malhotra J, Bagiella E, et al. Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens. Am J Hematol. 2014;89(6):616–620.
   PubMed Web of Science ®Google Scholar
• Caltagirone S, Ruggeri M, Aschero S, et al. Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. Haematologica. 2014;99(10):1611–1617.
   PubMed Web of Science ®Google Scholar
• Kriegova E, Fillerova R, Minarik J, et al. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep. 2021;11(1):14671.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Migkou M, Dalampira D, et al. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. Am J Hematol. 2022;97(9):1142–1149.
   PubMed Web of Science ®Google Scholar
• Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108(5):1724–1732.
   PubMed Web of Science ®Google Scholar
• Shah GL, Landau H, Londono D, et al. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leuk Lymphoma. 2017;58(8):1823–1831.
   PubMed Web of Science ®Google Scholar
• Abdallah N, Greipp P, Kapoor P, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4(15):3509–3519.
   PubMed Web of Science ®Google Scholar
• Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911–3920.
   PubMed Web of Science ®Google Scholar
• Xu J, Xu T, Yang Y, et al. The paradoxical prognostic role of 1q21 gain/amplification in multiple myeloma: every coin has two sides. Leuk Lymphoma. 2020;61(10):2351–2364.
   PubMed Web of Science ®Google Scholar
• Lamont EB, Yee AJ, Goldberg SL, Siegel DS, Norden AD. Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort. JNCI Cancer Spectr. 2021;5: pkaa111.
   Web of Science ®Google Scholar
• Klein U, Jauch A, Hielscher T, et al. Chromosomal aberrations 1q + 21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer. 2011;117(10):2136–2144.
   PubMed Web of Science ®Google Scholar
• Locher M, Steurer M, Jukic E, et al. The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event. Am J Hematol. 2020;95(12):1562–1571.
   PubMed Web of Science ®Google Scholar
• Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940–948.
   PubMed Web of Science ®Google Scholar
• Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159–170.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhou D, Xu J, et al. Prognostic value of 1q21 gain in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(3):e159–e164.
   PubMed Web of Science ®Google Scholar
• An G, Xu Y, Shi L, et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014;99(2):353–359.
   PubMed Web of Science ®Google Scholar
• Li X, Chen W, Wu Y, et al. 1q21 gain combined with high-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: a multicenter study in China. Oncologist. 2019;24(11):e1132–e1140.
   PubMed Web of Science ®Google Scholar
• Ross FM, Avet-Loiseau H, Ameye G, et al. Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97(8):1272–1277.
   PubMed Web of Science ®Google Scholar
• Martin T, Richardson PG, Facon T, et al. Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA. Haematologica. 2022;107(10):2485–2491.
   PubMed Web of Science ®Google Scholar
• An G, Li Z, Tai YT, et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015;21(9):2148–2156.
   PubMed Web of Science ®Google Scholar
• Gao L, Liu Y, Li Y, et al. The importance of FISH signal cut-off value and copy number variation for 1q21 in newly diagnosed multiple myeloma: is it underestimated? Clin Lymphoma Myeloma Leuk. 2022;22(7):535–544.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu J, Xu B, et al. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: the faster, the worse. Cancer. 2023;129(7):1005–1016.
   PubMed Web of Science ®Google Scholar
• Gao W, Jian Y, Du J, et al. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: a multicenter study in China. Cancer Med. 2020;9(21):7819–7829.
   PubMed Web of Science ®Google Scholar
• Weinhold N, Kirn D, Seckinger A, et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016;101(3):e116-119–e119.
   Web of Science ®Google Scholar
• Grzasko N, Hus M, Chocholska S, et al. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leuk Lymphoma. 2012;53(12):2500–2503.
   PubMed Web of Science ®Google Scholar
• Ouyang J, Gou X, Ma Y, et al. Prognostic value of 1p deletion for multiple myeloma: a meta-analysis. Int J Lab Hematol. 2014;36(5):555–565.
   PubMed Web of Science ®Google Scholar
• Wu KL, Beverloo B, Lokhorst HM, et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol. 2007;136(4):615–623.
   PubMed Web of Science ®Google Scholar
• Qazilbash MH, Saliba RM, Ahmed B, et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 2007;13(9):1066–1072.
   PubMed Web of Science ®Google Scholar
• Chang H, Jiang A, Qi C, et al. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma. 2010;51(11):2084–2091.
   PubMed Web of Science ®Google Scholar
• Nahi H, Vatsveen TK, Lund J, et al. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. Eur J Haematol. 2016;96(1):46–54.
   PubMed Web of Science ®Google Scholar
• Wang YT, Bao L, Chu B, et al. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis. J Clin Lab Anal. 2022;36:e24375.
   PubMed Web of Science ®Google Scholar
• Tang HKK, Fung CY, Morgan GJ, et al. The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain. Ther Adv Hematol. 2022;13:20406207221082043.
   Web of Science ®Google Scholar
• Schmidt TM, Barwick BG, Joseph N, et al. Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9(12):94.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130(24):2610–2618.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021;39(22):2430–2442.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Poenisch W, Knop S, et al. Ixazomib-thalidomide-dexamethasone for induction therapy followed by ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. Br J Cancer. 2019;121(9):751–757.
   PubMed Web of Science ®Google Scholar
• Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32(1):102–110.
   PubMed Web of Science ®Google Scholar
• D'Agostino M, Ruggeri M, Aquino S, et al. Impact of gain and amplification of 1q in newly diagnosed multiple myeloma patients receiving carfilzomib-based treatment in the forte trial. Blood. 2020;136(Supplement 1):38–40.
   Google Scholar
• Kapoor P, Schmidt T, Jacobus S, et al. OAB-052: impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial. Clinical Lymphoma Myeloma and Leukemia. 2021;21: S33–S34.
   Web of Science ®Google Scholar
• Varma A, Sui D, Milton DR, et al. Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: propensity score matched analysis. Biol Blood Marrow Transplant. 2020;26(4):665–671.
   PubMed Web of Science ®Google Scholar
• Scott EC, Hari P, Sharma M, et al. Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis. Biol Blood Marrow Transplant. 2016;22(10):1893–1899.
   PubMed Web of Science ®Google Scholar
• Hu X, Wu CH, Cowan JM, et al. Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy. Ann Hematol. 2022;101(2):369–378.
   PubMed Web of Science ®Google Scholar
• Mohan M, Weinhold N, Schinke C, et al. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol. 2020;189(1):67–71.
   PubMed Web of Science ®Google Scholar
• Barbieri E, Maccaferri M, Leonardi G, et al. Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience. Ann Hematol. 2022;101(12):2777–2779.
   PubMed Web of Science ®Google Scholar
• Parrondo RD, Gardner LB, Alhaj Moustafa M, et al. Therapeutic outcomes of relapsed-refractory multiple myeloma patients with 1q21+ treated with daratumumab-based regimens: a retrospective analysis. Blood. 2022;140(Supplement 1):7237–7238.
   Google Scholar
• Harrison SJ, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021;194(1):120–131.
   PubMed Web of Science ®Google Scholar
• Spicka I, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. J Clin Oncol. 2021;39(15_suppl):8042–8042.
   Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811–1822.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211). J Clin Oncol. 2022;40(16_suppl):8054–8054.
   Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021;127(22):4198–4212.
   PubMed Web of Science ®Google Scholar
• Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed/refractory multiple myeloma. Ann Hematol. 2023;102(1):1–11.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Riecken K, Wolschke C, et al. Development of CAR-T cell therapies for multiple myeloma. Leukemia. 2020;34(9):2317–2332.
   PubMed Web of Science ®Google Scholar
• D'Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia. 2020;34(1):21–34.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhou L, Zhao H, et al. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy. Clin Cancer Res. 2021;27(23):6384–6392.
   PubMed Web of Science ®Google Scholar
• Tang Y, Yin H, Zhao X, et al. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J Exp Clin Cancer Res. 2022;41(1):2.
   PubMed Web of Science ®Google Scholar
• Slomp A, Moesbergen LM, Gong JN, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 2019;3(24):4202–4214.
   PubMed Web of Science ®Google Scholar
• Pan D, Kaufman JL, Htut M, et al. Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. Cancer Med. 2022;11(2):358–370.
   PubMed Web of Science ®Google Scholar
• Richard S, Chari A, Delimpasi S, et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by cytogenetic risk. Am J Hematol. 2021;96(9):1120–1130.
   PubMed Web of Science ®Google Scholar